Literature DB >> 15774547

Inflammation suppressor genes: please switch out all the lights.

Christine A Wells1, Timothy Ravasi, David A Hume.   

Abstract

An effective immune system requires rapid and appropriate activation of inflammatory mechanisms but equally rapid and effective resolution of the inflammatory state. A review of the canonical host response to gram-negative bacteria, the lipopolysaccharide-Toll-like receptor 4 signaling cascade, highlights the induction of repressors that act at each step of the activation process. These inflammation suppressor genes are characterized by their induction in response to pathogen, typically late in the macrophage activation program, and include an expanding class of dominant-negative proteins derived from alternate splicing of common signaling components. Despite the expanse of anti-inflammatory mechanisms available to an activated macrophage, the frailty of this system is apparent in the large numbers of genes implicated in chronic inflammatory diseases. This apparent lack of redundancy between inflammation suppressor genes is discussed with regard to evolutionary benefits in generating a heterogeneous population of immune cells and consequential robustness in defense against new and evolving pathogens.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15774547     DOI: 10.1189/jlb.1204710

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  31 in total

1.  Systems biology of innate immunity.

Authors:  Jesper Tegnér; Roland Nilsson; Vladimir B Bajic; Johan Björkegren; Timothy Ravasi
Journal:  Cell Immunol       Date:  2007-04-11       Impact factor: 4.868

2.  Macrophage glucocorticoid receptors regulate Toll-like receptor 4-mediated inflammatory responses by selective inhibition of p38 MAP kinase.

Authors:  Sandip Bhattacharyya; Diane E Brown; Judson A Brewer; Sherri K Vogt; Louis J Muglia
Journal:  Blood       Date:  2007-01-25       Impact factor: 22.113

3.  Inhibition of RAW264.7 macrophage inflammatory cytokines release by small hairpin RNAi targeting TLR4.

Authors:  Hui Wang; Jinxiang Zhang; Heshui Wu; Chunfang Jiang; Qichang Zheng; Zhuoya Li
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

Review 4.  Shaping of monocyte and macrophage function by adenosine receptors.

Authors:  György Haskó; Pál Pacher; Edwin A Deitch; E Sylvester Vizi
Journal:  Pharmacol Ther       Date:  2006-09-14       Impact factor: 12.310

5.  Multiscale model for the assessment of autonomic dysfunction in human endotoxemia.

Authors:  Panagiota T Foteinou; Steve E Calvano; Stephen F Lowry; Ioannis P Androulakis
Journal:  Physiol Genomics       Date:  2010-03-16       Impact factor: 3.107

6.  Diversification of TOLLIP isoforms in mouse and man.

Authors:  Yu-Lan S Lo; Anthony G Beckhouse; Sharon L Boulus; Christine A Wells
Journal:  Mamm Genome       Date:  2009-05-15       Impact factor: 2.957

7.  Agent-based modeling of endotoxin-induced acute inflammatory response in human blood leukocytes.

Authors:  Xu Dong; Panagiota T Foteinou; Steven E Calvano; Stephen F Lowry; Ioannis P Androulakis
Journal:  PLoS One       Date:  2010-02-18       Impact factor: 3.240

8.  Construction of a large scale integrated map of macrophage pathogen recognition and effector systems.

Authors:  Sobia Raza; Neil McDerment; Paul A Lacaze; Kevin Robertson; Steven Watterson; Ying Chen; Michael Chisholm; George Eleftheriadis; Stephanie Monk; Maire O'Sullivan; Arran Turnbull; Douglas Roy; Athanasios Theocharidis; Peter Ghazal; Tom C Freeman
Journal:  BMC Syst Biol       Date:  2010-05-14

9.  In silico simulation of corticosteroids effect on an NFkB- dependent physicochemical model of systemic inflammation.

Authors:  Panagiota T Foteinou; Steve E Calvano; Stephen F Lowry; Ioannis P Androulakis
Journal:  PLoS One       Date:  2009-03-10       Impact factor: 3.240

10.  BOL-303242-X, a novel selective glucocorticoid receptor agonist, with full anti-inflammatory properties in human ocular cells.

Authors:  Jin-Zhong Zhang; Megan E Cavet; Karl R VanderMeid; Mercedes Salvador-Silva; Francisco J López; Keith W Ward
Journal:  Mol Vis       Date:  2009-12-08       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.